Fate Therapeutics, Inc.

NasdaqGM:FATE Lagerbericht

Marktkapitalisierung: US$240.1m

Fate Therapeutics Management

Management Kriterienprüfungen 2/4

Fate Therapeutics CEO ist Bob Valamehr , ernannt in Jan 2025, hat eine Amtszeit von 1.42 Jahren. Die jährliche Gesamtvergütung beträgt $2.25M , bestehend aus 26.7% Gehalt und 73.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.098% der Aktien des Unternehmens, im Wert von $236.49K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.4 Jahre bzw. 7.1 Jahre.

Wichtige Informationen

Bob Valamehr

Geschäftsführender

US$2.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts26.68%
Amtszeit als Geschäftsführer1.4yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements1.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.1yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • May 12

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Summary Fate Therapeutics, Inc. is downgraded from Strong Buy to Hold due to slower-than-expected clinical progress in its FT819 program for SLE. Phase 1 FT819-102 study shows promising efficacy with significant SLEDAI-2K score reductions, but patient enrollment and expansion to Regimen B remain limited. Regulatory catalysts, including potential phase 2 registration-enabling study initiation, are not expected until 2H 2026, delaying near-term value inflection. FATE maintains strong cash reserves through 2027 and has reduced operating expenses, but clinical and regulatory risks persist across its pipeline. Read the full article on Seeking Alpha
Analyseartikel • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
Analyseartikel • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
Analyseartikel • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
Analyseartikel • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
Analyseartikel • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
Analyseartikel • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
Analyseartikel • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
Analyseartikel • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
Analyseartikel • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
Analyseartikel • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Sep 22

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 30

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Summary Fate Therapeutics has potential inflection points stemming from clinical trial and regulatory momentum in the next 6-12 months. For those taking speculative positions within healthcare, this could present with potential upsides post-event(s). Those investors looking for a defensive overlay within healthcare might find weakness in FATE's measures of corporate value. With these points in mind, we rate FATE a hold with a $21 per share valuation. Investment summary There are selective opportunities located within the healthcare universe for investors taking both speculative and defensive positions. In either sense, factor rotations in H2 FY22 corroborate that value remains a thematic favorite for investors, adding a layer of resiliency to portfolios. Measures examining corporate value are therefore of upmost importance for equity investors looking ahead, in order to decipher the quality of earnings and business model one is allocating to. With this in mind, we examined Fate Therapeutics, Inc. (FATE) and found that it offers potential upsides from clinical trial and regulatory momentum over the next 6-12 months. For those on the speculative side, this is ideal. However, we also noted that for those seeking a defensive beta name in healthcare, FATE might not be the best choice, due to lack of profitability and unsupportive valuations from forward earnings. With opportunity costs front of mind, but also acknowledging the strengths in FATE's wider offering, we rate FATE a hold with a price target of $21. Exhibit 1. FATE 6-month price action Data: Refinitiv Eikon Q2 earnings indicative of regulatory, fundamental momentum Fundamental momentum is creeping up alongside regulatory momentum for FATE. Despite this, its earnings do need some cleaning up to reflect a more accurate snapshot. Revenue obtained via collaborations with Janssen and Ono Pharmaceutical (OPHLY) rose to $18.5 million in Q2 FY22, a 38% growth YoY. Meanwhile, the company saw a ~67% YoY headwind at the G&A line with expenditures increasing to $20.4 million. However, breaking down the increase in G&A, ~34% or $6.9 million ($0.07/share) was attributed to stock based compensation ("SBC"), up $4.3 million from this time last year. Operating expenses were also comprised of $81.3 million in R&D spend, that we argue should be capitalized and treated as an investment on the balance sheet [discussed later]. All in, SBC comprised $20.5 million of the $101.6 million in operating spend for the quarter. On the regulatory front, FATE achieved its first clinical milestone in its CAR T-cell product candidate, FT819. This is under an amended license agreement with Memorial Sloan Kettering Cancer Centre ("MSK"). The first milestone payment to MSK was activated following this milestone. This is important as there could be an additional 2 milestone payments obliged to MSK that are based on trading volumes of the company's stock in ranges of $100-$150/share. Changes in the fair value of these instruments is booked as income or expenditure by FATE and is therefore worth keeping an eye on from period to period and make necessary adjustments if necessary. Exhibit 2. FT819 descriptive overview Data: Fate Therapeutics Website Meanwhile, the Phase 1 trial of FATE's FY596 in combination with rituximab exhibited favorable safety data in both the single dose and dual-dose cohorts. Safety data held up well up to 900 million cells per dose, and the higher-dose regime could well be the protocol looking ahead, by estimate. From here FATA will continue to evaluate dosages for maximal therapeutic effect, with the next moves being a 3-dose cohort at a dose of 1.8 billion cells. We are intrigued to observe the outcome of the increased cellular load, particularly as the clinical protocol permits further dose escalation In terms of regulatory catalysts, investors should keep an eye out for the company's FT516 RMAT Type-B multidisciplinary meeting with the FDA this coming quarter. From here we'll have better understanding on the registrational pathways for the off-shelf programs against refractory aggressive B-cell lymphoma. Patients will include those whose disease is refractory or relapsed after previous treatment from other CD19 targeted CAR T-cell therapies. Reconciliations for accurate valuation We've identified a number of adjustments that need to be made in order to accurately value FATE, in order to understand exactly what it is we're buying. Firstly, R&D expenditure came in at $81 million for the quarter, up from $48 million YoY. We argue that R&D expenditure should be capitalized and amortized as an intangible asset, as it is an investment set to create future economic value. This has implications to earnings and investment for the company. However, we also found we can't capitalize FATE's entire R&D spend. Notably, the $33 million YoY increase in R&D stemmed from: $4.9 million increase in employee SBC expense to $13.57 million $9 million increase in spend to third-party professional consultants $8.6 million increase in expenditures for laboratory materials and supplies relating to the manufacture of product candidates and conduct of research activities. Therefore, we can only advocate to capitalize $67.4 million of R&D as an investment, seeing as SBC is an expense in our eyes. This has implications for both earnings and valuation, as discussed below. In addition, the company's drug product manufacturing facility in California has now opened with engineering runs underway. This is a tangible source of value that will supply drug products for companies conducting pivotal trials. In all, the company has $580 million in tangible book value with this included. Exhibit 3. Data & Image: HB Insights Valuation Being a clinical stage biopharma company, valuation ideally comprises a number of factors to obtain a corporate value for the company. However, we aren't confident on the predictability of estimating the prospective value of FATE's pipeline or working in terms of what's 'possible'. Instead, what's real and 'probable' are better terms to work by. With that, we observe corporate valuation in terms of earnings and investment; what's real and what's expected. We record this in shorthand with multiples of book value and earnings estimates. Instead, we are focusing on what we'd be buying today in FATE.
Seeking Alpha • Jul 28

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Needham has initiated coverage on Fate Therapeutics (NASDAQ:FATE) with a hold rating citing the potential of its stem cell cancer therapies. Fate develops induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells, which can address several challenges in cell therapy. They are off-the-shelf as opposed to current CAR-T therapies and allow for large-scale manufacturing and relatively easier genetic engineering. Analyst Gil Blum wrote, " Fate's lead programs in B-cell lymphomas and acute myeloid leukemia have potential in ~35,000 patients combined and have demonstrated promising early data. Even assuming cellular therapeutic pricing (~$300K in the US) and achievement of significant market penetration, we find FATE shares fully valued at this time." "Early POC was achieved in both BCL and AML. However, questions regarding treatment durability remain. We consider Fate's platform a compelling solution in solid tumors, despite NK iPSCs having low activity at baseline. Reports of clinical activity in solid tumors could be transformational for Fate," Blum adds. Needham's neutral rating on FATE is in line with SA Quant rating of hold. Shares dipped -5.46% to $31.36 today

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bob Valamehr im Vergleich zu den Einnahmen von Fate Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$130m

Dec 31 2025US$2mUS$600k

-US$136m

Sep 30 2025n/an/a

-US$156m

Jun 30 2025n/an/a

-US$172m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$4mUS$525k

-US$186m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$3mUS$500k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$3mUS$455k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$6mUS$430k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$2mUS$390k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$3mUS$375k

-US$98m

Vergütung im Vergleich zum Markt: BobDie Gesamtvergütung ($USD2.25M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.64M).

Entschädigung vs. Einkommen: BobDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Bob Valamehr (49 yo)

1.4yrs
Amtszeit
US$2,248,568
Vergütung

Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Bahram Valamehr
President1.4yrsUS$2.25m0.098%
$ 236.5k
Kamal Adawi
CFO & Treasurerless than a yearUS$1.11m0%
$ 0
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary10.7yrsUS$1.11m0.54%
$ 1.3m
Jessica Francis
Senior Vice President of Human Resources & Operations1.4yrskeine Datenkeine Daten
Martin Hosking
Head of Researchless than a yearkeine Datenkeine Daten
Tunde Babalola
Senior Vice President of Technical Operations & Quality1.4yrskeine Datenkeine Daten
Ryan Douglas
Senior Director of Investor Relations & Business Developmentless than a yearkeine Datenkeine Daten
Andrew Henry
Senior Vice President of Clinical Operations2.4yrskeine Datenkeine Daten
Yu Cai
Head of Intellectual Property & Assistant General Counsel1.4yrskeine Datenkeine Daten
Kate Duvall
Corporate Controller1.2yrskeine Datenkeine Daten
1.4yrs
Durchschnittliche Betriebszugehörigkeit
51yo
Durchschnittliches Alter

Erfahrenes Management: FATEDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.4 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Bahram Valamehr
President1.4yrsUS$2.25m0.098%
$ 236.5k
William Rastetter
Independent Chairman14.6yrsUS$142.98k0.55%
$ 1.3m
Robert Epstein
Independent Director12.3yrsUS$123.71k0.031%
$ 74.8k
Michael Lee
Independent Director7.9yrsUS$104.09k0.0097%
$ 23.3k
Matthew Abernethy
Independent Director1.1yrsUS$151.61k0%
$ 0
Karin Jooss
Independent Director7.3yrsUS$118.96k0.0084%
$ 20.3k
Shefali Agarwal
Independent Director6.9yrsUS$115.09k0.0090%
$ 21.6k
Yuan Xu
Independent Director4.8yrsUS$111.52k0.0074%
$ 17.9k
7.1yrs
Durchschnittliche Betriebszugehörigkeit
55.5yo
Durchschnittliches Alter

Erfahrener Vorstand: FATEDie Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/15 12:35
Aktienkurs zum Tagesende2026/06/15 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Fate Therapeutics, Inc. wird von 25 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG